Prescribing psychotropic drugs to patients aged 80 and over;Réflexions sur l'usage des psychotropes chez la personne très âgée

Revue Medicale Suisse

Volumn 4, Issue 178, 2008, Pages 2405-2411

  Hillleret, Henriette ^a   Falconnet, Catherine ^a   Le Saint, Laurent ^a   Perrenoud, Jean Jacques ^a   Michel, Jean Pierre ^a   Vogt Ferrier, Nicole ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOTIAPINE; FLUOXETINE; GABAPENTIN; HALOPERIDOL; LEVOMEPROMAZINE; MIRTAZAPINE; NEUROLEPTIC AGENT; NORFLUOXETINE; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TRANQUILIZER; TRAZODONE; VENLAFAXINE;

DOCTOR PATIENT RELATION; FAMILY; FRAIL ELDERLY; GERIATRIC PATIENT; PATIENT CARE; POLYPHARMACY; PRESCRIPTION; PSYCHOLOGY; PSYCHOMETRY; PSYCHOTHERAPY; REVIEW; TREATMENT INDICATION;

AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DRUG INTERACTIONS; FRAIL ELDERLY; HUMANS; POLYPHARMACY; PSYCHOTROPIC DRUGS;

EID: 56349160056     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Lalive d'Epinay C. Les années fragiles. Quebec, Canada, Ed. Presses de l'Université LAVAL, 2008.
2. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and drug administration. PLoS Med 2008;5:e45. doi:10.1371/journal.pmed.0050045.
3. Turner EH, Matthews AM, Linardatos, E et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
4. Widmer N, Csajka C, Werner D, et al. Suivi thérapeutique des médicaments (1): les principes. Rev Med Suisse 2008;4:1644-8.
5. Tableau des interactions médicamenteuses. Centre d'informations thérapeutiques et de pharmacovigilance, Service de pharmacologie et toxicologie cliniques, Hôpitaux universitaires 1211 Genève 14. http://pharmacoclin.hug-ge.ch/activites_clinique/pharma_outils.html
6. Anonymes. Stratégie: enrichir sa panoplie thérapeutique, bilan 2005. Prescrire 2006;26:50-3. Ibidem, bilan 2007. Prescrire 2008;28:39-40 et 47-8.
7. Anonymes. Vigilance: venlafaxine et risque cardiaque. Prescrire 2005;25:105.
8. Anonymes. Venlafaxine: gravité des surdoses. Prescrire 2007;27:22.
9. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20.
10. Benoit M, Andrieu S, Lechowski L, et al. Apathy and depression in Alzheimer's disease are associated with functional deficits and psychotropic prescriptions. Int J Geriatr Psychiatry 2008;23:409-14.
11. ** Van Zyl LT, Seitz P. Delirium: Concisely, condition is associated with increased morbidity, mortality and length of hospitalisation. Geriatrics 2006;61:18-21.
12. Rochon PA, Normand SL, Gomes T, et al. Anti-psychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008;168:1090-6.
13. Zhong KX, Tariot PN, Mintzer J, et al. Quetiapine to treat agitation in dementia: A randomized, double blind, placebo-controlled study. Curr Alzheimer Res 2007;4: 81-93.
14. Alexopoulos GS, Streim JE, Carpenter D. Expert consensus guidelines for using antipsychotic agents in older patients. J Clin Psychiatry 2004;65(Suppl. 2):100-2.
15. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: Self controlled case series study. BMJ 2008;337:a1227-8.
16. Anonymes. Personnes âgées démentes: moins de neuroleptiques. Prescrire 2007:27:293.
17. NICE (National institute for clinical excellence). Violence. The short-term management of disturbed violent behavior in in-patient psychiatric settings and emergency departments. Clinical Guideline 25 février 2005, (80 pages).
18. ** Jacobson SA, Pies RW, Katz IR. Clinical geriatric psychopharmacology. Arlington: Ed. American Psychiatric Publishing 2007;506.
19. Abnormal involuntary movement scale (AIMS): Psychopharmacology research branch, NIMH. In Guy W. Ed ECDEU Assessment manual for psychopharmacology, revised DHEW Pub No (ADM) 76-338, Rockville, MD: National institute of mental health, 1976, 534-7. Cité dans Burns A, Lawlor B, Craig S. Assessment scales in old age. Londres: Ed. Martin Dunitz.
20. Rossi P, Serrao M, Pozzessere G. Gabapentin-induced worsening of neuropsychiatric symptoms in dementia with Lewy bodies: Case reports. Eur Neurol 2002; 47:56-7.
21. Kim Y, Wilkins KM, Tampi RR. Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: A review of the evidence. Drugs Aging 2008;25:187-96.
22. Moretti R, Torre P, Antonello RM, et al. Gabapentin for the treatment of behavioural alterations in dementia: Preliminary 15-month investigation. Drugs Aging 2003;20:1035-40.
23. Parsons B, Tive L, Huang S. Gabapentine: A pooled analysis of adverse events from three clinical trials in patients with post herpetic neuralgia. Am J Ger Pharmacotherapy 2004;2:157-62.
24. Kanbay M, Kaya A, Bozolan R, and al. Gabapentin induced edema in a geriatric patient. Clin Neuropharmacology 2006;29:186.
25. Glass J, et al. Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ 2005;331:1169-73.
26. Anonyme. Vigilance:mirtazapine:neutropenics, etc. Prescrire 2007;27:746.
27. Anonymes. Vigilance: syndromes démentiels: des psychotropes ou d'autres médicaments. Prescrire 2007; 27:832.
28. Haute autorité de santé, France. Modalités d'arrêt des benzodiazepines chez les patients âgés. Guide disponible sur www.has-sante.fr et décrit dans Prescrire 2008;28:229.